SMARCA4 and glioblastoma: Similarly, as found in adult glioblastomas (35), CRISPR-based LOF and pharmacologic inhibition of SMARCA4 revealed that SMARCA4 is required to maintain characteristics of H3K27M-driven diffuse midline glioma (DMG) (36).